R. Kates

发表

European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.

N. Harbeck, A. Dunant, M. Joore, 2016, European journal of cancer.

Activator Inhibitor Type 1 (n = 3424) Urokinase-type Plasminogen Activator (uPA) and Plasminogen Cancer Patients Classified High-Risk according to Enhanced Benefit from Adjuvant Chemotherapy in Breast

N. Harbeck, R. Kates, 2013 .

Tumor-Associated Proteolytic Factors uPA and PAI-1: Critical Appraisal of Their Clinical Relevance in Breast Cancer and Their Integration into Decision-Support Algorithms

H. Allgayer, N. Harbeck, M. Schmitt, 2007, Critical reviews in clinical laboratory sciences.

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer

Manfred Schmitt, Nadia Harbeck, Marion Kiechle, 2004, Thrombosis and Haemostasis.

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

M. Kiechle, N. Harbeck, F. Jänicke, 2002, Clinical breast cancer.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

J. Foekens, J. Klijn, M. Look, 2002, Cancer research.

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

N. Brünner, M. Fernö, J. Foekens, 2002, Journal of the National Cancer Institute.

Clinical Relevance of the Plasminogen Activator Inhibitor Type1 – a Multifaceted Proteolytic Factor

A. Krüger, N. Harbeck, F. Jänicke, 2001, Oncology Research and Treatment.

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.

M. Kiechle, N. Harbeck, O. Gluz, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

S. Shak, F. Baehner, N. Harbeck, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial

F. Marmé, S. Linn, N. Harbeck, 2016, International journal of cancer.

Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma

E. Diamandis, N. Harbeck, M. Schmitt, 2006 .

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

D. Wallwiener, R. Kreienberg, M. Kiechle, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet

T. Fehm, N. Harbeck, O. Gluz, 2020, Breast Care.

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

N. Harbeck, O. Gluz, R. Kates, 2013, Trials.

Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

S. Shak, N. Harbeck, O. Gluz, 2015 .

Pooled analysis (n=8,377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer.

J. Foekens, M. Look, N. Harbeck, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer

N. Harbeck, M. Untch, C. Thomssen, 2013, Breast Cancer Research and Treatment.

Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.

S. Shak, N. Harbeck, O. Gluz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients

N. Brünner, M. Fernö, J. Foekens, 2003, Thrombosis and Haemostasis.

Invasion F actors u PA/PAI-1 a nd H ER2 S tatus P rovide Independent a nd C omplementary I nformation o n P atient Outcome i n N ode-Negative B reast C ancer

M. Kiechle, N. Harbeck, P. Dettmar, 2003 .

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

H. Höfler, M. Kiechle, N. Harbeck, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PTK7 Expression in Triple-negative Breast

W. Eiermann, N. Harbeck, R. Kates, 2013 .

PTK7 expression in triple-negative breast cancer.

W. Eiermann, N. Harbeck, R. Kates, 2013, Anticancer research.

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.

S. Shak, N. Harbeck, O. Gluz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery

J. Slotta-Huspenina, E. Diamandis, M. Kiechle, 2014, Oncology letters.

Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients

A. Scorilas, E. Diamandis, M. Kiechle, 2007, Clinical Cancer Research.

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

M. Dieci, N. Harbeck, O. Gluz, 2020, Cancers.

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

P. Fasching, L. Häberle, T. Fehm, 2022, British Journal of Cancer.

S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.

S. Shak, N. Harbeck, O. Gluz, 2011 .

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

F. Feuerhake, N. Harbeck, O. Gluz, 2022, Breast cancer research : BCR.

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

I. Zuna, N. Harbeck, O. Gluz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

N. Harbeck, O. Gluz, S. Kuemmel, 2016 .

Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

O. Gluz, S. Kuemmel, C. Liedtke, 2016 .

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

N. Harbeck, O. Gluz, S. Kuemmel, 2018, Journal of the National Cancer Institute.

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

M. Ellis, M. Dowsett, J. Robertson, 2020, npj Breast Cancer.

Improvement of Safety Profile of Docetaxel by Weekly Administration in Patients with Metastatic Breast Cancer

N. Harbeck, R. Ohlinger, R. Kates, 2007, Oncology Research and Treatment.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

N. Harbeck, O. Gluz, S. Kuemmel, 2017 .

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.

N. Harbeck, O. Gluz, S. Kuemmel, 2022, The Lancet. Oncology.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

N. Harbeck, O. Gluz, S. Kuemmel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

S. Shak, N. Harbeck, O. Gluz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial.

N. Harbeck, O. Gluz, A. Hartmann, 2013 .

Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.

N. Harbeck, O. Gluz, C. Liedtke, 2015 .

Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer.

A. Scorilas, E. Diamandis, M. Kiechle, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.

E. Diamandis, N. Harbeck, M. Schmitt, 2006, Biological chemistry.

Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

F. Feuerhake, M. Hauptmann, N. Harbeck, 2021, Journal for ImmunoTherapy of Cancer.

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

N. Harbeck, M. Schmitt, R. Kates, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β

F. Feuerhake, N. Harbeck, O. Gluz, 2018, Laboratory Investigation.

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and

J. Foekens, J. Nährig, J. Martens, 2007, European journal of cancer.

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.

N. Harbeck, O. Gluz, R. Kates, 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

N. Harbeck, O. Gluz, S. Kuemmel, 2021, Cancer medicine.

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

S. Shak, F. Baehner, N. Harbeck, 2020, Therapeutic advances in medical oncology.

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

F. Baehner, N. Harbeck, O. Gluz, 2020, Cancer.

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

N. Harbeck, O. Gluz, S. Kuemmel, 2019, International journal of cancer.

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

J. Nährig, A. Ullrich, M. Kiechle, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

N. Harbeck, O. Gluz, C. Poremba, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.

E. Warner, I. Andrulis, P. Goss, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Advanced statistical methods for the definition of new staging models.

Ronald Kates, Manfred Schmitt, Nadia Harbeck, 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer

H. Allgayer, S. Post, R. Kates, 2007, Clinical Cancer Research.

Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial

N. Harbeck, O. Gluz, A. Hartmann, 2011, Breast Cancer Research and Treatment.

Challenging tumour aggressiveness – Individualising patient management

N. Harbeck, F. Jänicke, C. Thomssen, 2008 .

Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse

H. Höfler, N. Harbeck, K. Ulm, 1999, Breast Cancer Research and Treatment.

Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

H. Höfler, A. Krüger, N. Harbeck, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

M. Ellis, M. Dowsett, J. Robertson, 2020, npj Breast Cancer.

Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.

M. Rezai, S. Shak, N. Harbeck, 2014 .

LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials

O. Gluz, S. Kuemmel, A. Hartkopf, 2022, Annals of Oncology.

ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).

N. Harbeck, O. Gluz, S. Kuemmel, 2019 .

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

S. Shak, N. Harbeck, O. Gluz, 2017, Breast Cancer Research and Treatment.

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial

N. Brünner, M. Kiechle, N. Harbeck, 2015, Breast Cancer Research and Treatment.

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

N. Harbeck, O. Gluz, S. Kuemmel, 2021, Cancers.

Pooled analysis of two randomized phase III trials (PlanB/SuccessC) comparing six cycles of docetaxel and cyclophosphamide to sequential anthracycline taxane chemotherapy in patients with intermediate and high risk HER2-negative early breast cancer (n=5,923).

P. Fasching, T. Fehm, A. Schneeweiss, 2018 .

The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer

H. Tesch, J. Hornberger, N. Harbeck, 2016, Current medical research and opinion.

Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients

N. Harbeck, R. Kates, Anke Thomas, 2010, Breast Cancer Research and Treatment.

Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.

M. Hoopmann, N. Harbeck, R. Kates, 2009, Oncology reports.

Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition.

A. Krüger, R. Kates, D. Edwards, 2010, Biochimica et biophysica acta.

Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients

N. Harbeck, O. Gluz, O. Stoetzer, 2020, Breast Care.

Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.

N. Harbeck, R. Kates, S. Paepke, 2007, Anticancer research.

Postoperative Sense of Well-Being and Quality of Life in Breast Cancer Patients Do not Depend on Type of Primary Surgery

N. Harbeck, R. Kates, S. Paepke, 2008, Oncology Research and Treatment.

Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.

M. Hoopmann, N. Harbeck, R. Kates, 2010, Anticancer research.

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

D. Wallwiener, M. Kiechle, N. Harbeck, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.

N. Harbeck, O. Gluz, S. Kuemmel, 2020 .

Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial

M. Hauptmann, S. Shak, N. Harbeck, 2021 .

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

F. Feuerhake, N. Harbeck, O. Gluz, 2022, Clinical Cancer Research.

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.

O. Gluz, S. Kuemmel, R. Kates, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

N. Harbeck, O. Gluz, S. Kuemmel, 2021 .

Abstract P4-10-05: Predictive value of HER2 expression, early response and tumor infiltrating lymphocytes (TILs) on efficacy of de-escalated pertuzumab+trastuzumab in the neoadjuvant WSG-ADAPT-HER2+/HR- trial

F. Feuerhake, N. Harbeck, O. Gluz, 2020 .

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.

N. Harbeck, O. Gluz, S. Kuemmel, 2023, JAMA oncology.

Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.

N. Harbeck, O. Gluz, C. Liedtke, 2017 .

Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

N. Harbeck, O. Gluz, C. Liedtke, 2018 .

Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals

R. Diasio, E. Gross, K. Seck, 2005, Clinical Cancer Research.

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study

K. Friedrichs, N. Harbeck, O. Gluz, 2019, Breast Cancer Research and Treatment.

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial

F. Feuerhake, S. Shak, N. Harbeck, 2020, Breast Cancer Research.

Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial

S. Shak, N. Harbeck, O. Gluz, 2012 .

LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial

F. Feuerhake, O. Gluz, S. Kuemmel, 2021 .

Decision Support in Breast Cancer: Recent Advances in Prognostic and Predictive Techniques

N. Harbeck, K. Ulm, M. Schmitt, 2000 .

Gynecological Cancers: A Challenge of Individualized Therapy in the Adjuvant and Palliative Setting

Quillien, I. Christensen, N. Harbeck, 2015 .

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs

A. Ullrich, W. Eiermann, N. Harbeck, 2014, OncoTargets and therapy.

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial

N. Harbeck, O. Gluz, S. Kümmel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial

N. Harbeck, O. Gluz, C. Liedtke, 2016 .

De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.

N. Harbeck, O. Gluz, S. Kuemmel, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

LBA14 De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab+ET in early HR+/HER2+ breast cancer (BC): ADAPT-TP survival results

M. Hauptmann, N. Harbeck, S. Kuemmel, 2020 .

Abstract P6-05-11: Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine

M. Rezai, S. Shak, N. Harbeck, 2013 .

Abstract P2-10-03: Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial

N. Harbeck, O. Gluz, S. Kuemmel, 2018 .

Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial

F. Feuerhake, N. Harbeck, O. Gluz, 2019, General Session Abstracts.

Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition.

H. Tesch, J. Hornberger, N. Harbeck, 2015 .

Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.

S. Shak, N. Harbeck, O. Gluz, 2017 .

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.

S. Shak, N. Harbeck, O. Gluz, 2012 .

Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2− Early Breast Cancer

N. Harbeck, R. Kates, D. Mayr, 2021, Journal of personalized medicine.

3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.

M. Hoopmann, N. Harbeck, R. Ohlinger, 2011, Anticancer research.

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

N. Harbeck, O. Gluz, C. Liedtke, 2015 .

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

F. Feuerhake, N. Harbeck, O. Gluz, 2022, Breast Cancer Research.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

D. Wallwiener, R. Kreienberg, M. Kiechle, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer

M. Kiechle, N. Harbeck, V. Magdolen, 2004, Thrombosis and Haemostasis.

Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast Cancer

A. Krüger, N. Harbeck, F. Jänicke, 2000, The International journal of biological markers.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

D. Wallwiener, R. Kreienberg, N. Harbeck, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

I. Zuna, O. Gluz, T. Reimer, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.